Fundamental Short Selling Research

Eric Fernandez, CFA

TwoRiversAnalytics

Equity Bottom-Up

<ul>
<li>Our breaking growth model uncovers slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance.</li>
<li>These shorts tend to have moderate to higher betas, time horizons of three to twelve months, higher valuations due to historically strong growth and are often “market darlings”.  </li>
<li>The short response, when growth breaks, is based on a downward reassessment of future growth potential frequently aided by multiple compression that accelerates the decline.</li>
</ul>


Our breaking growth model uncovers slowing growth, margin declines, sales and/or earnings disappointments, troubling working capital trends, poor estimate trends or lowered guidance.
These shorts tend to have moderate to higher betas, time horizons of three to twelve months, higher valuations due to historically strong growth and are often “market darlings”.  
The short response, when growth breaks, is based on a downward reassessment of future growth potential frequently aided by multiple compression that accelerates the decline.


United States

Insulet Corporation is a medical device company that develops, manufactures and markets an insulin infusion system for people with insulin-dependent diabetes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Insulet Corp (PODD US)

Breaking Growth Short Candidates

Get a glimpse into our short idea generation process through our Breaking Growth model update. This week: Insulet, Generac, Catalent and Wingstop...

Eric Fernandez, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)